Prosecution Insights
Last updated: April 19, 2026

Huyabio International LLC

5 pending office actions

Portfolio Summary

5
Total Pending OAs
2
Final Rejections
3
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18351439 COMBINATION THERAPIES OF WDR-5 INHIBITORS AND PD-1 INHIBITORS TOWNSLEY, SARA ELIZABETH 1629 Non-Final OA Jul 12, 2023
18120311 MLL1-WDR5 PROTEIN-PROTEIN INTERACTION INHIBITOR COMPOUNDS AND USES THEREOF ELENISTE, PIERRE PAUL 1622 Non-Final OA Mar 10, 2023
17993567 COMBINATION THERAPIES OF HDAC INHIBITORS AND PD-L1 INHIBITORS WU, JULIE ZHEN QIN 1643 Final Rejection Nov 23, 2022
17410459 METHODS AND COMPOSITIONS FOR GENETIC MODULATION OF TUMOR MICROENVIRONMENTS PECKHAM, RICHARD GRANT 1627 Final Rejection Aug 24, 2021
16894532 TRIPLET THERAPIES OF HDAC INHIBITORS, PD-L1 AND/OR PD-1 INHIBITORS, AND CTLA-4 INHIBITORS BUTTICE, AUDREY L 1647 Non-Final OA Jun 05, 2020

Managing Huyabio International LLC's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month